Thirty patients with bulky advanced ovarian cancer surgically not resectable, received combination chemotherapy (median of 4.1 cycles; range, 3-7) including cisplatin or carboplatin, followed by a second surgical effort. Clinical CR+PR was observed in 24/30 (80 %) patients after chemotherapy. Our study deals only with these 24 patients, and the 6 patients who did not respond to chemotherapy are not part of this report. At debulking, 7/24 (29.1 %) patients had a complete macroscopic resection; 9/24 (37.5 %) patients had a partial resection (residual tumor <2 cm). These data suggest that debulking is feasible and successful after chemotherapy containing cisplatin or its derivative. Overall median survival from diagnosis was 18.9 months; the 3-year survival rate was 28 %. Median progression-free survival from diagnosis was 13.5 months. The results observed in our study indicate that the use of induction chemotherapy can play an important role in increasing the chances of optimal debulking in patients presenting with unresectable ovarian cancer.
Get full access to this article
View all access options for this article.
References
1.
CohenC.J., GolbergJ.D., HollandJ.F. and 4 others: Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second-look operation).Am. J. Obstet. Gynecol.,145: 955–967, 1983.
2.
ContéP.F., BruzzoneM., ChiaraS., and 31 others: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.J. Clin. Oncol.,4: 965–971, 1986.
3.
ContéP.F., BruzzoneM., ChiaraS. and 7 others: A randomized study comparing carboplatin (CBDCA), doxorubicin (DX) and cytoxan (C) (CAC) versus cisplatin (CDDP), doxorubicin and cytoxan (PAC) in stage III-IV epithelial ovarian cancer.Proc. Am. Soc. Clin. Oncol.,6: 463 (p. 118 abstract), 1987.
4.
CopelandL.J., GershensonD.M.: Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy.Obstet. Gynecol.,68: 873–874, 1986.
5.
DemboA.J.: Controversy over combination chemotherapy in advanced ovarian cancer; what we learn from reports of matured data.J. Clin. Oncol.,4: 1573–1576, 1986.
6.
GehanE.A.: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples.Biometrika,52: 203–217, 1965.
7.
GriffithsC.T., ParkerL.M., FullenA.F.: Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.Cancer Treat. Rep.,63: 235–240, 1979.
8.
HoA.G., BellerU., SpeyerJ.L., ColomboN., WernzJ., BeckmanE.M.: A reassessment of the role of second look laparotomy in advanced ovarian cancer.J. Clin. Oncol.,5: 1316–1321, 1987.
9.
KaplanE., MeierP.: Non parametric estimation from incomplete observations.J. Am. Statist. Assoc.,53: 457–481, 1958.
10.
KatzM.E., SchwartzP.E., KappD.S., LuikartS.: Epithelial carcinoma of the ovary: current strategies.Ann. Intern. Med.,95: 98–111, 1981.
11.
LawtonF.G., StuartN., MouldJ.J., ChetiyawardanaA.D., ChanK.K., LatiefT., SpoonerD., BlackledgeG.: Improved treatment of inoperable epithelial ovarian cancer - results of a combined modality programme.Br. J. Cancer,54: 204–207, 1986.
12.
LawtonF.G., KellyK.A., Sant CassiaL.J., BlackledgeG.: Speed of response to platinum-based chemotherapy: implications for the management of epithelial ovarian cancer.Eur. J. Cancer Clin. Oncol.,23: 1071–1075, 1987.
13.
LouieK.G., OzolsR.F., MyersC.E., OstchegaY., JenkinsJ., HowserD., YongR.C.: Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.J. Clin. Oncol., 4III: 1579–1585, 1986.
14.
MeadG.M., WilliamsC.J., MacbethF.R., BoydI.E., White-houseJ.M.A.: Second look laparotomy in the management of epithelial cell carcinoma of the ovary.Br. J. Cancer,50: 185–191, 1984.
15.
MillerD.S., BallonC.S., TengN.N., SeiferD.B., SorieroO.M.: A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma.Cancer,57: 530–537, 1986.
16.
NeijtJ.P., Ten Bokkel HuininkW.W., Van der BurgM. and 8 others: Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.Lancet,2: 594–600, 1984.
17.
NeijtJ.P., Ten Bokkel HuininkW.W., Van der BurgM.E.L., and 8 others: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma.J. Clin. Oncol.,5: 1157–1168, 1987.
18.
ParkerL.M., GriffithsC.T., JanisD., WelchE.R., GelmanR.S., BastR.C., KnappR.C., CanellosG.P.: Advanced ovarian carcinoma: integration of surgical treatment and chemotherapy with cyclophosphamide, adriamycin and cis-diamminedichloroplatinum. Proc. Am. Assoc. Clin. Oncol., Abs. C., 599, 153, 1983.
19.
PetoR., PetoJ.: Asymptotically efficient rank invariant test procedures.J. R. Stat. Soc. A.,135: 185–198, 1972.
20.
PiverM.S.: Ovarian carcinoma. A decade of progress.Cancer,54: 2706–2715, 1984.
21.
RajuK.S., McKinnaJ.A., BarkerG.H., WiltshawE., JonesJ.M.: Second-look operations in the planned management of advanced ovarian carcinoma.Am. J. Obstet. Gynecol.,144: 650–654, 1982.
22.
RichardsonG.S., ScullyR.E., NikruiN., NelsonJ.H.Jr.: Common epithelial cancer of the ovary (part II).N. Engl. J. Med.,312: 474–483, 1985.
23.
SchrayJ.M., MartinezA., CoxR., BallonS.: Radiotherapy in epithelial ovarian cancer: analysis of prognostic factors based on long-term experience.Obstet. Gynecol.,62: 373–382, 1983.
24.
VoglS.E., SelzerV., CalanogA., MoukhtarM., CamachoF., KaplanB.H., GreenwaldE.: « Second-effort» surgical resection for bulky ovarian cancer.Cancer,54: III, 2220–2225, 1984.
25.
W.H.O.: Handbook for reporting results of cancer treatment. WHO Offset Publ. no. 48. WHO, Geneve, 1979.
26.
WilsJ., BlijhamG., NausA. and 24 others: Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.J. Clin. Oncol.,4: 1068–1073, 1986.
27.
WiltshawE.: Ovarian trials at Royal Marsden Hospital.Cancer Treat. Rev.,12: 67–71, 1985.
ZambettiM., BonadonnaG.: Principi di strategia e stato attuale degli studi terapeutici controllati nei tumori dell'ovaio. In: Neoplasie Ginecologiche, pp. 227–233, Casa Editrice Ambrosiana (Ed.), Milano, 1987.
